VIVUS, Inc. (NASDAQ:VVUS)

CAPS Rating: 2 out of 5

A pharmaceutical company dedicated to the development and commercialization of therapeutic products using patented proprietary formulations and novel delivery systems and by seeking new indications for previously approved pharmaceutical products.

Recs

0
Player Avatar ravens9111 (61.07) Submitted: 7/16/2012 11:26:58 AM : Underperform Start Price: $27.97 VVUS Score: +68.89

Betting against this stock's FDA decision tomorrow. Price is most likely already priced in for approval. I expect a sell the news event even if approval is granted. However, if rejected, this stock will go to low teens to high single digits.

Featured Broker Partners


Advertisement